Photo taken from Jun Gong/X
Jun 5, 2024, 09:58
Jun Gong: Dr. Cigliola PhII SURE trial of neoadj sacituzumab govitecan for cis-ineligible MIBC
Jun Gong, Medical Oncologist and Researcher in Gastrointestinal and Genitourinary cancers at Cedars-Sinai, shared a post on X:
“Dr. Cigliola PhII SURE trial of neoadj sacituzumab govitecan for cis-ineligible MIBC
18/21 patients finished all 4C 47.6% pCR rate but 3 deaths (1 treatment-related) after 1C, required amendment to lower dose and require GCSF, several patients with cCR.”
Source: Jun Gong/X
